Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
Saved in:
| Title: | Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. |
|---|---|
| Authors: | Anywaine Z; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Barry H; Centre MURAZ, Bobo-Dioulasso, Burkina Faso., Anzala O; KAVI - Institute of Clinical Research University of Nairobi, Nairobi, Kenya., Mutua G; KAVI - Institute of Clinical Research University of Nairobi, Nairobi, Kenya., Sirima SB; Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Unité de Recherche Clinique de Banfora, Banfora, Burkina Faso., Eholie S; Unit of Infectious and Tropical Diseases, BPV3, Treichville University Teaching Hospital, Abidjan, Côte d'Ivoire., Kibuuka H; Makerere University - Walter Reed Project, Kampala, Uganda., Bétard C; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France., Richert L; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.; Vaccine Research Institute (VRI), Créteil, France., Lacabaratz C; Vaccine Research Institute (VRI), Créteil, France.; Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Shukarev G; Janssen Vaccines and Prevention, Leiden, the Netherlands., Katwere M; Janssen Vaccines and Prevention, Leiden, the Netherlands., Robinson C; Janssen Vaccines and Prevention, Leiden, the Netherlands., Gaddah A; Janssen Research & Development, Beerse, Belgium., Heerwegh D; Janssen Research & Development, Beerse, Belgium., Bockstal V; Janssen Vaccines and Prevention, Leiden, the Netherlands., Luhn K; Janssen Vaccines and Prevention, Leiden, the Netherlands., Leyssen M; Janssen Vaccines and Prevention, Leiden, the Netherlands., Thiébaut R; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.; Vaccine Research Institute (VRI), Créteil, France., Douoguih M; Janssen Vaccines and Prevention, Leiden, the Netherlands. |
| Corporate Authors: | EBL2002 Study group |
| Source: | PLoS medicine [PLoS Med] 2022 Jan 11; Vol. 19 (1), pp. e1003865. Date of Electronic Publication: 2022 Jan 11 (Print Publication: 2022). |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-1676 |
|---|---|
| DOI: | 10.1371/journal.pmed.1003865 |
